We found that RUNX1 is more strongly expressed in CN-AML patients than in normal bone marrow (NBM), but also was an unfavorable prognostic factor in two large, independent groups of patients with CN-AML. The gene discussed is RUNX1; the disease is acute myeloid leukemia.